ArticleVeterinary research2026
Multivalent Disabled Infectious Single Animal (DISA)-DIVA vaccine for all nine serotypes of African horse sickness virus (AHSV) is broadly protective in IFNAR (-/-) mice.
Article in Veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African horse sickness (AHS) is a highly severe, midge-borne disease of equids showing a mortality rate of > 90% in naive domestic horses. Outbreaks are caused by AHS virus (AHSV) and result in devastating economic losses in developing countries as equids play a crucial role in the agricultural industry and many households. The AHSV species encompasses nine serotypes showing no or limited cross protection, which is challenging regarding AHS vaccine development. Recently, and like bluetongue virus (BTV), the AHS Disabled Infectious Single Animal (DISA)-DIVA vaccine platform was developed and applied for all nine AHSV serotypes. The vaccine platform is based on a single deletion crucial for vaccine safety and affording differentiation of infected from vaccinated individuals (DIVA) testing. Before considering ethically debatable and expensive experiments in equids, DISA-DIVA vaccine candidates were evaluated here in the previously validated IFNAR (-/-) mouse model for AHS. A multivalent AHS DISA-DIVA vaccine containing DISA constructs for each of the nine serotypes was studied. This "DISA cocktail" was safe and protected mice against two virulent AHSV serotypes used in challenge infection studies. DISA multivalent vaccine induced serotype-specific neutralizing antibodies (nAbs) against all AHSV serotypes suggesting broad protection, as correlates of protection (CoP) based on nAb titers for studied serotypes can be extrapolated to others. These results now justify further experiments in horses to study safety, efficacy and DIVA by DISA cocktail vaccine. Importantly, the presented results for IFNAR (-/-) mice indicate that broad protection of equines by vaccination with DISA cocktail vaccine can be feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.